Journal
CLINICAL INFECTIOUS DISEASES
Volume 52, Issue 3, Pages E18-E55Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciq146
Keywords
-
Categories
Funding
- Cubist
- Ortho-McNeil
- Pfizer
- Theravance
- Targanta
- Astellas
- AdvanDx
- Clorox
- Sanofi Pasteur
- Sage
- GeneOhm
- Cubist Pharmaceuticals
- Merck
- Wyeth
- Johnson Johnson
- Sanofi-Aventis
- Vicuron Pharmaceuticals
- Wyeth-Ayerst
- Theravance/Astellas
Ask authors/readers for more resources
Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available